ArticleBMC chemistry2025
Non-invasive quantification of methadone in exhaled breath condensates using PtNPs/AgNP-modified GCE: an electrochemical sensor for narcotic bioanalysis.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Methadone (MTD) is a synthetic opioid frequently used to treat opioid addiction. The therapeutic use of this drug must be prescribed carefully because, in addition to toxicity, its suboptimal use can cause addiction. Therefore, there is an urgent need to fabricate reliable methods for sensitive and specific recognition of MTD in biological fluids. In this study, a novel platinum nanoparticles (PtNPs)/cluster-like-AgNPs/glassy carbon electrode (GCE)-based electrochemical sensor was developed for quantifying MTD in human exhaled breath condensate (EBC) samples. After morphological characterization of the probe, the utilization of this platform for MTD detection was examined by cyclic voltammetry and square wave voltammetry techniques. The analyte-related electrochemical signal of the probe was linear at two linear ranges of 30 ng/mL to 0.1 µg/mL and 0.1 to 2.5 µg/mL with a limit of detection of 21 ng/mL. The validation results confirmed the high repeatability and accuracy with relative standard deviation and absolute relative error of 4.8% and 1.76%, respectively. Additionally, the specificity, stability, and reproducibility of the probe were studied under the Food and Drug Guidelines, approving the reliability of the probe for use in MTD detection in EBC samples. The engineered sensor (PtNPs/cluster-like-AgNPs/GCE) was successfully employed for the detection of MTD in human EBC samples. The results demonstrated the potential of the probe for non-invasive monitoring of MTD in patient EBC samples. The main limitation of the probe is its low reusability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.